We have developed our own target selection algorithm, which goes under the name Abiprot Select™.
- Target Selection criteria: The target must either be clinically validated or have compelling evidence of efficacy from human genetics studies. 80 % of our targets have clinically documented efficacy, and 20% are new disruptive targets with compelling scientific credentials.
Our biologics technology platform, Abiprot™, together with Abiprot Select™ approaches the development of therapeutic antibodies differently as illustrated below. Compared to traditional methods, AbiProt Select™ has the potential of benefitting cost-effectivity, risk reduction and revenue.